Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia

Tapan M. Kadia, Farhad Ravandi, Matteo Molica, Alex Bataller, Gautam Borthakur, Naval Daver, Elias Jabbour, Courtney D. DiNardo, Naveen Pemmaraju, Nitin Jain, Alessandra Ferrajoli, Musa Ylimaz, Prithviraj Bose, Rebecca Slack Tidwell, Kayleigh R. Marx, Caitlin R. Rausch, Rashmi Kanagal-Shamanna, Sa Wang, Rabiul Islam, Richard ChamplinElizabeth Shpall, Marina Konopleva, Guillermo Garcia-Manero, Hagop Kantarjian

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences